2. Academic Validation
  3. DNAJB4 suppresses breast cancer progression and promotes tumor immunity by regulating the Hippo signaling pathway

DNAJB4 suppresses breast cancer progression and promotes tumor immunity by regulating the Hippo signaling pathway

  • Discov Oncol. 2023 Aug 7;14(1):144. doi: 10.1007/s12672-023-00762-8.
Yanru Chen # 1 2,  Jingjia Li # 1 2,  Lulan Pu # 1 2,  Jinghua Hu 1 2,  Lingyu Fang 1 2,  Fangfang Zhou 1 2,  Hongying Zhang 3,  Yi Yang 1 2,  Xinxin Rong 1 2,  Shishan Deng 4 5,  Lingmi Hou 6 7
Affiliations

Affiliations

  • 1 Academician (Expert) Workstation, Medical Imaging Key Laboratory of Sichuan Province, Biological Targeting Laboratory of Breast Cancer, Department of Breast and Thyroid Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
  • 2 Medical Imaging Key Laboratory of Sichuan Province, Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China.
  • 3 The Fifth People's Hospital of Nanchong City, Nanchong, Sichuan, China.
  • 4 Academician (Expert) Workstation, Medical Imaging Key Laboratory of Sichuan Province, Biological Targeting Laboratory of Breast Cancer, Department of Breast and Thyroid Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China. dengssgenral@163.com.
  • 5 Medical Imaging Key Laboratory of Sichuan Province, Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China. dengssgenral@163.com.
  • 6 Academician (Expert) Workstation, Medical Imaging Key Laboratory of Sichuan Province, Biological Targeting Laboratory of Breast Cancer, Department of Breast and Thyroid Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China. houlingmi@163.com.
  • 7 Medical Imaging Key Laboratory of Sichuan Province, Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China. houlingmi@163.com.
  • # Contributed equally.
PMID: 37548821 DOI: 10.1007/s12672-023-00762-8
Abstract

Purpose: Breast Cancer is the most common Cancer worldwide. Low DNAJB4 expression levels are strongly correlated with poor prognosis in breast Cancer patients. However, the molecular mechanism by which DNAJB4 regulates breast Cancer progression is unclear.

Methods: The expression of DNAJB4 was validated in human breast Cancer tissues, normal human breast tissues, and breast Cancer cell lines. CCK-8, colony-forming, and wound healing assays were used to assess the biological effect of DNAJB4 overexpression on cell proliferation and migration in MCF-7 cell lines. Bioinformatic analysis was used to identify the DNAJB4 related pathways in breast Cancer. Epithelial-mesenchymal transition (EMT)-related biomarkers and Hippo pathway components were quantified by Western blots. Luciferase and Western blot assays were used to validate which miRNA regulates DNAJB4. In addition, the effects of DNAJB4 on in vivo tumor growth were assessed in xenograft models.

Results: DNAJB4 was expressed at low levels in human breast Cancer tissues and breast Cancer cell lines and correlated with poor prognosis. DNAJB4 overexpression significantly inhibited cell proliferation and migration in vitro by activating the Hippo pathway. The dual-luciferase assay showed that hsa-miR-183-5p targeted DNAJB4. Moreover, the effects of DNAJB4 could be reversed by miR-183-5p. In addition, the expression of DNAJB4 was strongly correlated with immune infiltration levels. Notably, DNAJB4 overexpression markedly enhanced CD4 + and CD8 + T cells and reduced PD-L1 levels in 4T1 tumors via the Hippo pathway, which retarded tumor growth in a subcutaneous xenograft tumor mouse model of 4T1 cells.

Conclusions: The present study demonstrated that DNAJB4 overexpression inhibited the malignant biological behavior of breast Cancer by regulating the Hippo pathway and tumor immunosuppressive environment.

Keywords

Breast cancer; DNAJB4; Hippo pathway; Migration; Proliferation; Tumor immunity.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-138489
    99.98%, Lat1/2 kinases Inhibitor
    YAP